NCT01685281View on ClinicalTrials.gov

Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
ADHD Predominantly Inattentive Type
Interventions
DRUG

Metadoxine (MG01CI)

MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo

DRUG

Placebo

Placebo tablets will be similar in appearance (color and size) to the investigational product

Trial Locations (1)

Unknown

Geha Medical Centre, Petah Tikva

All Listed Sponsors
lead

Alcobra Ltd.

INDUSTRY

NCT01685281 - Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder | Biotech Hunter | Biotech Hunter